CONCORDBIO2024-04-012024-06-30 CONCORDBIO2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member CONCORDBIO2024-06-30 CONCORDBIO2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CONCORDBIO2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543960 CONCORDBIO NA Concord Biotech Limited Equity 2024-04-01 2025-03-31 2024-08-09 2024-07-31 INR Lakhs First quarter 11:00:00 12:15:00 2024-08-09 2024-08-09 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Consolidated 2158017000.00 103077000.00 2261094000.00 550338000.00 117784000.00 -185131000.00 316639000.00 2408000.00 131785000.00 545600000.00 1479423000.00 781671000.00 0.00 781671000.00 193941000.00 5344000.00 199285000.00 0.00 582386000.00 0.00 0.00 0.00 13545000.00 595931000.00 1693000.00 597624000.00 595931000.00 0.00 597624000.00 0.00 104616000.00 1 5.70 5.70 0.00 0.00 5.70 5.70 Notes to the statement of unaudited consolidated financial results for the quarter ended June 30, 2024 : 1. The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on August 9, 2024. The Statutory Auditors of the company have carried out a limited review of the said results. 2.The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended December 31, 2023 which were subjected to limited review. 3. The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - Operating Segment . 4. The above results has been prepared in accordance with Indian Accounting Standards ( IND AS ) notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines Issued by the Securities and Exchange Board of India ( SEBI ). Other Expenses 545600000.00 Re-measurement gain/ (loss) on defined benefit plans 2262000.00 Income tax relating to Re-measurement gain/ (loss) on defined benefit plans -569000.00 1693000.00 0.00 0.00